Go Pro
→ They didn't warn anyone in 1971. This time someone is warning you. (From Reagan Gold Group) (Ad)tc pixel

Compare Stocks

Compare stocks with our powerful stock comparison tool. Analyze fundamentals, price performance, and key financial indicators to make informed investment decisions. Our tool lets you compare up to ten stocks side by side based on Performance Charts, Price & Volume, MarketRank™, Analyst Ratings, Sales & Book Value, Profitability & Earnings, Dividends, Debt, Ownership, Headlines, and more. Simply enter up to ten stock symbols (e.g., BAC, JPM, WFC, C, GS) to get started and uncover top investment opportunities.

Compare
CompanyCurrent Price50-Day Moving Average52-Week RangeMarket CapBetaAvg. VolumeToday's Volume
AlloVir, Inc. stock logo
ALVR
AlloVir
$4.08
+5.2%		$4.23
$7.96
▼
$24.15
$20.58M0.6315,685 shs28,090 shs
Celularity, Inc. stock logo
CELU
Celularity
$0.70
+0.0%		$0.72
$0.56
▼
$4.31
$20.14M0.5440,768 shs17,556 shs
Ernexa Therapeutics Inc. stock logo
ERNA
Ernexa Therapeutics
$4.06
-4.9%		$5.42
$3.18
▼
$71.50
$6.97M2.5762,886 shs27,419 shs
Skye Bioscience, Inc. stock logo
SKYE
Skye Bioscience
$0.42
-17.2%		$0.65
$0.28
▼
$4.99
$17.62M2.97459,041 shs9.38 million shs
7 Stocks That Could Lead the Next Market Boom Cover
7 Stocks That Could Lead the Next Market Boom

Tesla, Nvidia, and Google helped shape the last era of market growth, but the next wave could come from a new group of companies. Inside this report, you’ll find 7 stocks that could play a major role in the next tech-driven market boom.

Get This Free Report

Compare Price Performance

Company1-Day Performance7-Day Performance30-Day Performance90-Day Performance1-Year Performance
AlloVir, Inc. stock logo
ALVR
AlloVir
0.00%+0.25%-6.85%-13.92%+65.85%
Celularity, Inc. stock logo
CELU
Celularity
+0.03%+1.37%-10.80%-13.66%-80.00%
Ernexa Therapeutics Inc. stock logo
ERNA
Ernexa Therapeutics
-4.92%-10.38%-36.76%-64.54%-89.75%
Skye Bioscience, Inc. stock logo
SKYE
Skye Bioscience
-17.23%-22.05%-36.07%-42.76%-88.17%
CompanyCurrent Price50-Day Moving Average52-Week RangeMarket CapBetaAvg. VolumeToday's Volume
AlloVir, Inc. stock logo
ALVR
AlloVir
$4.08
+5.2%		$4.23
$7.96
▼
$24.15
$20.58M0.6315,685 shs28,090 shs
Celularity, Inc. stock logo
CELU
Celularity
$0.70
+0.0%		$0.72
$0.56
▼
$4.31
$20.14M0.5440,768 shs17,556 shs
Ernexa Therapeutics Inc. stock logo
ERNA
Ernexa Therapeutics
$4.06
-4.9%		$5.42
$3.18
▼
$71.50
$6.97M2.5762,886 shs27,419 shs
Skye Bioscience, Inc. stock logo
SKYE
Skye Bioscience
$0.42
-17.2%		$0.65
$0.28
▼
$4.99
$17.62M2.97459,041 shs9.38 million shs
7 Stocks That Could Lead the Next Market Boom Cover
7 Stocks That Could Lead the Next Market Boom

Tesla, Nvidia, and Google helped shape the last era of market growth, but the next wave could come from a new group of companies. Inside this report, you’ll find 7 stocks that could play a major role in the next tech-driven market boom.

Get This Free Report

Compare Price Performance

Company1-Day Performance7-Day Performance30-Day Performance90-Day Performance1-Year Performance
AlloVir, Inc. stock logo
ALVR
AlloVir
0.00%+0.25%-6.85%-13.92%+65.85%
Celularity, Inc. stock logo
CELU
Celularity
+0.03%+1.37%-10.80%-13.66%-80.00%
Ernexa Therapeutics Inc. stock logo
ERNA
Ernexa Therapeutics
-4.92%-10.38%-36.76%-64.54%-89.75%
Skye Bioscience, Inc. stock logo
SKYE
Skye Bioscience
-17.23%-22.05%-36.07%-42.76%-88.17%
CompanyConsensus Rating ScoreConsensus RatingConsensus Price Target% Upside from Current Price
AlloVir, Inc. stock logo
ALVR
AlloVir
0.00
N/AN/AN/A
Celularity, Inc. stock logo
CELU
Celularity
2.00
Hold$6.00762.07% Upside
Ernexa Therapeutics Inc. stock logo
ERNA
Ernexa Therapeutics
2.00
Hold$30.00638.92% Upside
Skye Bioscience, Inc. stock logo
SKYE
Skye Bioscience
2.20
Hold$8.001,827.25% Upside

Current Analyst Ratings Breakdown

Latest ERNA, CELU, ALVR, and SKYE Analyst Ratings

DateCompanyBrokerageActionRatingPrice TargetDetails
8/5/2026
Celularity, Inc. stock logo
CELU
Celularity
Weiss Ratings logo
Weiss Ratings
Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating
DowngradeSell (D-) ➝ Sell (E+)
7/17/2026
Ernexa Therapeutics Inc. stock logo
ERNA
Ernexa Therapeutics
Weiss Ratings logo
Weiss Ratings
Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating
Reiterated RatingSell (E+)
7/10/2026
Skye Bioscience, Inc. stock logo
SKYE
Skye Bioscience
Weiss Ratings logo
Weiss Ratings
Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating
Reiterated RatingSell (D-)
7/6/2026
Celularity, Inc. stock logo
CELU
Celularity
Weiss Ratings logo
Weiss Ratings
Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating
UpgradeSell (E+) ➝ Sell (D-)
(Data available from 8/18/2023 forward. View 10+ years of historical ratings with our analyst ratings screener.)
CompanyAnnual RevenuePrice/SalesCashflowPrice/CashBook ValuePrice/Book
AlloVir, Inc. stock logo
ALVR
AlloVir
N/AN/AN/AN/A$29.35 per shareN/A
Celularity, Inc. stock logo
CELU
Celularity
$26.55M0.76N/AN/A($1.32) per share-0.53
Ernexa Therapeutics Inc. stock logo
ERNA
Ernexa Therapeutics
$580K11.41N/AN/A$7.64 per share0.53
Skye Bioscience, Inc. stock logo
SKYE
Skye Bioscience
N/AN/AN/AN/A$0.62 per shareN/A
CompanyNet IncomeEPSTrailing P/E RatioForward P/E RatioP/E GrowthNet MarginsReturn on Equity (ROE)Return on Assets (ROA)Next Earnings Date
AlloVir, Inc. stock logo
ALVR
AlloVir
-$190.42M-$20.23N/AN/AN/AN/A-71.03%-61.27%N/A
Celularity, Inc. stock logo
CELU
Celularity
-$91.72M-$3.33N/AN/AN/A-345.45%N/A-77.94%8/18/2026 (Estimated)
Ernexa Therapeutics Inc. stock logo
ERNA
Ernexa Therapeutics
-$14.08M-$14.35N/AN/AN/AN/A-305.93%-169.86%11/6/2026 (Estimated)
Skye Bioscience, Inc. stock logo
SKYE
Skye Bioscience
-$55.92M-$1.27N/AN/AN/AN/A-244.83%-170.10%N/A

Latest ERNA, CELU, ALVR, and SKYE Earnings

DateQuarterCompanyConsensus EstimateReported EPSBeat/MissGap EPSRevenue EstimateActual RevenueDetails
8/14/2026Q2 2026
Skye Bioscience, Inc. stock logo
SKYE
Skye Bioscience
-$0.29-$0.27+$0.02-$0.3070N/AN/A
8/6/2026Q2 2026
Ernexa Therapeutics Inc. stock logo
ERNA
Ernexa Therapeutics
-$3.30-$3.40-$0.10-$3.40N/AN/A
5/20/2026Q1 2026
Ernexa Therapeutics Inc. stock logo
ERNA
Ernexa Therapeutics
-$1.95-$6.95-$5.00-$6.95N/AN/A
CompanyAnnual PayoutDividend Yield5-Year Annualized Dividend GrowthPayout RatioYears of Consecutive Growth
AlloVir, Inc. stock logo
ALVR
AlloVir
N/AN/AN/AN/AN/A
Celularity, Inc. stock logo
CELU
Celularity
N/AN/AN/AN/AN/A
Ernexa Therapeutics Inc. stock logo
ERNA
Ernexa Therapeutics
N/AN/AN/AN/AN/A
Skye Bioscience, Inc. stock logo
SKYE
Skye Bioscience
N/AN/AN/AN/AN/A
CompanyDebt-to-Equity RatioCurrent RatioQuick Ratio
AlloVir, Inc. stock logo
ALVR
AlloVir
N/A
86.78
86.78
Celularity, Inc. stock logo
CELU
Celularity
N/A
0.15
0.15
Ernexa Therapeutics Inc. stock logo
ERNA
Ernexa Therapeutics
N/A
2.01
2.01
Skye Bioscience, Inc. stock logo
SKYE
Skye Bioscience
N/A
1.78
1.78

Institutional Ownership

CompanyInstitutional Ownership
AlloVir, Inc. stock logo
ALVR
AlloVir
66.05%
Celularity, Inc. stock logo
CELU
Celularity
19.02%
Ernexa Therapeutics Inc. stock logo
ERNA
Ernexa Therapeutics
70.55%
Skye Bioscience, Inc. stock logo
SKYE
Skye Bioscience
21.09%

Insider Ownership

CompanyInsider Ownership
AlloVir, Inc. stock logo
ALVR
AlloVir
32.07%
Celularity, Inc. stock logo
CELU
Celularity
17.30%
Ernexa Therapeutics Inc. stock logo
ERNA
Ernexa Therapeutics
0.53%
Skye Bioscience, Inc. stock logo
SKYE
Skye Bioscience
6.20%
CompanyEmployeesShares OutstandingFree FloatOptionable
AlloVir, Inc. stock logo
ALVR
AlloVir
1105.04 million3.43 millionNo Data
Celularity, Inc. stock logo
CELU
Celularity
22028.95 million23.94 millionOptionable
Ernexa Therapeutics Inc. stock logo
ERNA
Ernexa Therapeutics
101.63 million1.62 millionNo Data
Skye Bioscience, Inc. stock logo
SKYE
Skye Bioscience
1135.14 million32.97 millionOptionable

Recent News About These Companies

Skye Bioscience, Inc. (SKYE) M&A Call Prepared Remarks Transcript
August 14, 2026  |  seekingalpha.comhttps://seekingalpha.com/article/4936945-skye-bioscience-inc-skye-m-and-a-call-prepared-remarks-transcript
Skye Bioscience and Redx Pharma Announce Transaction Agreement and $125 Million in Financings
August 14, 2026  |  globenewswire.comhttps://www.globenewswire.com/news-release/2026/08/14/3345392/0/en/skye-bioscience-and-redx-pharma-announce-transaction-agreement-and-125-million-in-financings.html
Skye Bioscience, Inc. (NASDAQ:SKYE) Receives Average Recommendation of "Moderate Buy" from Brokerages
August 7, 2026  |  americanbankingnews.comhttps://www.americanbankingnews.com/?p=30945749
Pomerantz LLP Commences Class Action Against Skye Bioscience, Inc. – SKYE
July 12, 2026  |  natlawreview.comN
Cadrenal Therapeutics Names Sharp Interim CFO
June 29, 2026  |  marketwatch.comhttps://www.marketwatch.com/story/cadrenal-therapeutics-names-sharp-interim-cfo-d989c809
Skye Bioscience Expands Authorized Shares After Shareholder Approval
May 29, 2026  |  tipranks.comhttps://www.tipranks.com/news/company-announcements/skye-bioscience-expands-authorized-shares-after-shareholder-approval?utm_source=marketbeat.com&utm_medium=referral
Skye Announces Cohort Review Committee Approved Opening of Cohort 2 Based on Favorable Safety Data from First Four Participants Treated in Cohort 1
May 20, 2026  |  globenewswire.comhttps://www.globenewswire.com/news-release/2026/05/20/3298335/0/en/skye-announces-cohort-review-committee-approved-opening-of-cohort-2-based-on-favorable-safety-data-from-first-four-participants-treated-in-cohort-1.html
Skye Bioscience (SKYE) price target decreased by 11.48% to 7.87
May 14, 2026  |  msn.comhttps://www.msn.com/en-us/money/topstocks/skye-bioscience-skye-price-target-decreased-by-1148-to-787/ar-AA23efXu
Analysts’ Opinions Are Mixed on These Healthcare Stocks: Coherus Biosciences (CHRS), Moderna (MRNA) and Skye Bioscience (SKYE)
May 14, 2026  |  theglobeandmail.comhttps://www.theglobeandmail.com/investing/markets/stocks/MRNA/pressreleases/1894362/analysts-opinions-are-mixed-on-these-healthcare-stocks-coherus-biosciences-chrs-moderna-mrna-and-skye-bioscience-skye/
Skye Bioscience, Inc.: Skye Bioscience Reports First Quarter 2026 Financial Results and Business Update
May 14, 2026  |  finanznachrichten.dehttps://www.finanznachrichten.de/nachrichten-2026-05/68466082-skye-bioscience-inc-skye-bioscience-reports-first-quarter-2026-financial-results-and-business-update-399.htm
Pomerantz LLP Files Investor Lawsuit Against Skye Bioscience, Inc. – SKYE
May 13, 2026  |  natlawreview.comN
Skye Bioscience Initiates CBeyond™ Expansion Study (Part C) with Planned Review on May 18, 2026
May 12, 2026  |  quiverquant.comQ
UPDATE – Skye Bioscience Reports First Quarter 2026 Financial Results and Business Update
May 12, 2026  |  globenewswire.comhttps://www.globenewswire.com/news-release/2026/05/12/3293281/0/en/update-skye-bioscience-reports-first-quarter-2026-financial-results-and-business-update.html
Skye Bioscience Reports First Quarter 2026 Financial Results and Business Update
May 11, 2026  |  globenewswire.comhttps://www.globenewswire.com/news-release/2026/05/11/3292287/0/en/skye-bioscience-reports-first-quarter-2026-financial-results-and-business-update.html
Kuehn Law Encourages Investors of Skye Bioscience, Inc. to Contact Law Firm
April 22, 2026  |  globenewswire.comhttps://www.globenewswire.com/news-release/2026/04/22/3279089/0/en/kuehn-law-encourages-investors-of-skye-bioscience-inc-to-contact-law-firm.html
Skye Bioscience Presenting at GLP-1-Based Therapeutics Summit
April 7, 2026  |  globenewswire.comhttps://www.globenewswire.com/news-release/2026/04/07/3268967/0/en/skye-bioscience-presenting-at-glp-1-based-therapeutics-summit.html
Skye Bioscience Treats First Patient in Nimacimab Higher-Dose Expansion Study Evaluating Exposure-Response to Inform Phase 2b Dose Selection for GLP-1 Combination Development
April 2, 2026  |  globenewswire.comhttps://www.globenewswire.com/news-release/2026/04/02/3267226/0/en/skye-bioscience-treats-first-patient-in-nimacimab-higher-dose-expansion-study-evaluating-exposure-response-to-inform-phase-2b-dose-selection-for-glp-1-combination-development.html
Skye Bioscience Inc (SKYE) Q4 2025 Earnings Call Highlights: Pioneering Advances in Obesity ...
March 11, 2026  |  finance.yahoo.comhttps://finance.yahoo.com/news/skye-bioscience-inc-skye-q4-010448378.html
Skye Bioscience, Inc.: Skye Bioscience Reports Fourth Quarter and Full Year 2025 Financial Results and Provides Business Update
March 11, 2026  |  finanznachrichten.dehttps://www.finanznachrichten.de/nachrichten-2026-03/67912990-skye-bioscience-inc-skye-bioscience-reports-fourth-quarter-and-full-year-2025-financial-results-and-provides-business-update-399.htm
Skye Bioscience outlines 2026 milestones as nimacimab advances toward Phase IIb with new dosing strategy
March 11, 2026  |  msn.comhttps://www.msn.com/en-us/health/other/skye-bioscience-outlines-2026-milestones-as-nimacimab-advances-toward-phase-iib-with-new-dosing-strategy/ar-AA1XWwMY

New MarketBeat Followers Over Time

Media Sentiment Over Time

Top Headlines

View All Headlines
Stack of office folders stamped “UPGRADED,” symbolizing rising analyst ratings for stocks like Micron in 2026.
These 3 Most-Upgraded Stocks Have Almost Nothing to Do With AI
By Leo Miller | August 10, 2026
Illuminated Marriott logo and sign at the entrance of a hotel building at dusk.
Marriott’s Earnings Drop May Be Missing the Bigger Fee Growth Story
By Chris Markoch | August 4, 2026
Intel logo glowing above a detailed microchip surface in a high-tech semiconductor lab.
Intel Earnings Reveal Whether the Chip Selloff Created a Buy
By Chris Markoch | July 24, 2026
Illustration of a PayPal vault opened to reveal a glowing PYUSD coin, with a Stripe and Advent International acquisition proposal folder nearby.
PayPal Rejected a $53 Billion Takeover Bid: Is the Stock Undervalued?
By Jessica Mitacek | July 22, 2026
Large outdoor display shows a declining red stock price chart amid downtown office towers with pedestrians walking nearby.
Asian Market Circuit Breakers Hit Stocks, Not AI Demand
By Jeffrey Neal Johnson | August 13, 2026
AlloVir stock logo

AlloVir NASDAQ:ALVR

$4.08 +0.20 (+5.15%)
As of 08/14/2026

AlloVir, Inc. engages in the research, development and commercialization of off-the-shelf VST therapies to prevent and treat severe viral-associated diseases. It develops novel cell therapies with a focus on restoring natural immunity against life-threatening virus-associated diseases in patients with severely weakened immune systems. The firm's technology platforms deliver commercially scalable solutions by leveraging off-the-shelf, allogeneic, multi-virus specific T-cells targeting devastating viral pathogens for immunocompromised patients under viral attack. The company was founded by Malcolm K. Brenner, Juan F. Vera, Helen E. Heslop, Cliona M. Rooney, John R. Wilson, and Ann M. Leen in August 2013 and is headquartered in Waltham, MA.

Celularity stock logo

Celularity NASDAQ:CELU

$0.70 +0.00 (+0.03%)
Closing price 08/17/2026 04:00 PM Eastern
Extended Trading
$0.70 +0.00 (+0.57%)
As of 07:46 AM Eastern
Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Massive. Learn more.

Celularity Inc., a clinical-stage biotechnology company, develops off-the-shelf placental-derived allogeneic cell therapies for the treatment of cancer, immune, and infectious diseases. It operates through three segments: Cell Therapy, Degenerative Disease, and BioBanking. The company's lead therapeutic programs include CYCART-19, an allogeneic CAR-T cell for the treatment of non-Hodkin's lymphoma (NHL) and mantle cell lymphoma (MCL); CYNK-001, an allogeneic unmodified natural killer cell that is in Phase I/II clinical trial for the treatment of acute myeloid leukemia (AML); and APPL-001, a genetically modified placental-derived mesenchymal-like adherent stromal cell for the treatment of Crohn's disease. It is also developing CYCART-201 for the treatment of NHL and MCL, and human epidermal growth factor receptor 2 positive cancers; CYNK-301, a next generation chimeric antigen receptor-natural killer (CAR-NK) for treating relapse refractory AML; CYNK-302, a CAR-NK to treat non-small cell lung cancer; and pExo-001, a human postpartum placenta derived exosome product for the treatment of osteoarthritis. It also produces, sells, and licenses products that are used in surgical and wound care markets, such as Biovance, Biovance 3L, Interfyl, and Centaflex; and collects and stores stem cells from umbilical cords and placentas under the LifebankUSA brand. The company has licensing agreement with Sorrento Therapeutics, Inc. for the development and commercialization of licensed CD19 CAR-T products; and research collaboration services agreement with Regeneron Pharmaceuticals, Inc. to support the research of allogeneic cell therapy candidates. The company was founded in 1998 and is based in Florham Park, New Jersey.

Ernexa Therapeutics stock logo

Ernexa Therapeutics NASDAQ:ERNA

$4.06 -0.21 (-4.92%)
Closing price 08/17/2026 04:00 PM Eastern
Extended Trading
$4.42 +0.37 (+8.99%)
As of 09:05 AM Eastern
Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Massive. Learn more.

Eterna Therapeutics Inc., a life science company, provides mRNA cell engineering technologies. Its technologies include mRNA cell reprogramming and gene editing; NoveSlice and UltraSlice gene-editing proteins; and the ToRNAdo mRNA delivery system. The company has a license agreement with Factor Bioscience Limited. Eterna Therapeutics Inc. was founded in 2018 and is based in Cambridge, Massachusetts.

Skye Bioscience stock logo

Skye Bioscience NASDAQ:SKYE

$0.42 -0.09 (-17.23%)
Closing price 08/17/2026 04:00 PM Eastern
Extended Trading
$0.38 -0.03 (-7.73%)
As of 09:14 AM Eastern
Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Massive. Learn more.

Skye Bioscience, Inc., a clinical stage pharmaceutical company, discovers, develops, and commercializes cannabinoid-based molecules for the treatment of infectious diseases. The company's lead product candidate is SBI-100 used in the treatment of glaucoma and ocular hypertension. It is also developing SBI-200 to treat and manage various eye diseases, including uveitis, dry eye syndrome, macular degeneration and diabetic retinopathy. It has license agreement with university of Mississippi. The company was formerly known as Emerald Bioscience, Inc. and changed its name to Skye Bioscience, Inc. in January 2021. The company is headquartered in San Diego, California.

Stock Comparison Ideas (A-K)

Stock Comparison Ideas (L-Z)

Stock Lists
Low Priced Stocks
Stocks By Exchange
Latest Stock Ideas